^
    4ms
    A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=400, Recruiting, BeiGene | N=200 --> 400
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab) • albumin-bound paclitaxel • pemetrexed • BGB-15025 • BGB-A445 • LBL-007
    4ms
    A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov)
    P1, N=88, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Aug 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • Inlyta (axitinib) • LBL-007
    4ms
    Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jul 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • LBL-007
    5ms
    BGB-HNSCC-201: Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=160, Recruiting, BeiGene
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • LBL-007 • surzebiclimab (BGB-A425)
    5ms
    BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, BeiGene | N=90 --> 120
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab) • pemetrexed • ociperlimab (BGB-A1217) • LBL-007
    5ms
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=226, Recruiting, BeiGene | Phase classification: P1b/2 --> P1/2
    Phase classification
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    5ms
    A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=116, Recruiting, BeiGene
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    cisplatin • paclitaxel • Tevimbra (tislelizumab) • LBL-007
    6ms
    A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=116, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    cisplatin • paclitaxel • Tevimbra (tislelizumab) • LBL-007
    8ms
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=226, Recruiting, BeiGene | Trial completion date: Aug 2026 --> Apr 2028 | Trial primary completion date: Feb 2025 --> Apr 2028
    Trial completion date • Trial primary completion date • Combination therapy • Mismatch repair • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    9ms
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=202, Recruiting, BeiGene | Active, not recruiting --> Recruiting
    Enrollment open • Combination therapy • Mismatch repair • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    10ms
    Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=160, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • LBL-007 • surzebiclimab (BGB-A425)
    11ms
    Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, BeiGene
    New P2 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • LBL-007 • surzebiclimab (BGB-A425)
    11ms
    Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • LBL-007
    11ms
    A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov)
    P1, N=88, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Aug 2023 --> Apr 2024 | Trial primary completion date: May 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Loqtorzi (toripalimab-tpzi) • Inlyta (axitinib) • LBL-007
    11ms
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=202, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Mismatch repair • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    12ms
    A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, BeiGene | Not yet recruiting --> Recruiting | N=300 --> 200 | Trial completion date: Nov 2025 --> Jul 2025 | Trial primary completion date: Nov 2025 --> Jul 2025
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab) • albumin-bound paclitaxel • pemetrexed • BGB-A445 • LBL-007
    1year
    Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • ociperlimab (BGB-A1217) • LBL-007
    over1year
    Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, BeiGene | Initiation date: Dec 2022 --> Mar 2023
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • ociperlimab (BGB-A1217) • LBL-007
    over1year
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=202, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Mismatch repair • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    over1year
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=202, Not yet recruiting, BeiGene | Initiation date: Nov 2022 --> Feb 2023
    Trial initiation date • Combination therapy • Mismatch repair • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    over1year
    A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, BeiGene
    New P2 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab) • albumin-bound paclitaxel • pemetrexed • BGB-A445 • LBL-007
    over1year
    Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, BeiGene
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • ociperlimab (BGB-A1217) • LBL-007
    over1year
    BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=358, Recruiting, BeiGene | N=162 --> 358 | Trial completion date: Jan 2024 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Mar 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • LBL-007 • surzebiclimab (BGB-A425)
    over1year
    A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov)
    P1, N=88, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Aug 2022 --> May 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Loqtorzi (toripalimab-tpzi) • Inlyta (axitinib) • LBL-007
    3years
    [VIRTUAL] Phase I study of LBL-007, a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody in patients with advanced solid tumors. (ASCO 2021)
    The dose escalation part of the study revealed tolerability of LBL-007 with an impressive safety profile, and potentially some encouraging signs of anti-tumor activities . Clinical trial: Chinaclinicaltrials.org.cn (1900025904).
    Clinical • P1 data
    |
    LAG3 (Lymphocyte Activating 3) • IL2 (Interleukin 2)
    |
    LBL-007